Compare Newmont Corporation (NEM) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Sanofi SA — how do they compare? Newmont Corporation trades at $117.95 (market cap $123.50B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Newmont Corporation is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| NEM | SNY | |
|---|---|---|
Market Cap | $123.50B | $104.30B |
Sector | Basic Materials | Health |
52-Week High | $131.95 | $52.34 |
52-Week Low | $67.38 | $41.33 |
Enterprise Value | $120.09B | $124.19B |
Dividend Yield | 0.89% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont (NEM) trades at $118.52, up 1.07% on the day, with strong earnings beats in recent quarters and a bullish analyst consensus. Technical indicators show mixed signals with RSI near overbought levels but moving averages supporting an uptrend. Recent news highlights resolution of a Nevada dispute with Barrick and solid Q2 2026 results, reinforcing operational stability.
Outlook remains positive with a $133 consensus price target, driven by robust cash flow and gold price strength. Risks include potential cost pressures and reliance on commodity cycles, but institutional buying and high buy ratings suggest confidence in near-term growth.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
